Storia in 2 fonti

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' - PTC Therapeutics (NASDAQ:PTCT

PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.

Raccontata da

biopharmadive.com

benzinga.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo10 h fa

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' - PTC Therapeutics (NASDAQ:PTCT

PTC acquires ST-920 gene therapy for Fabry from Sangamo for $111M upfront plus $100M milestones, FDA submission expected Q4 2026. De-risks pipeline by acquiring late-stage validated asset without R&D cost, supporting PTC's 2026 cash flow break-even target.

originale

biopharmadive.com1 g fa

PTC takes a chance on Sangamo’s Fabry disease gene therapy

PTC acquired gene therapy ST-920 for Fabry from bankrupt Sangamo for $111M upfront plus $100M in FDA milestones, targeting 2027 launch. Gene therapies remain viable; the $2B+ market and ST-920's edge justify PTC's rare-disease bet with infrastructure synergies.

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' - PTC Therapeutics (NASDAQ:PTCT

PTC takes a chance on Sangamo’s Fabry disease gene therapy

Timeline cronologica

PTC takes a chance on Sangamo’s Fabry disease gene therapy

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity' - PTC Therapeutics (NASDAQ:PTCT